2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
1Univ of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…2015 American Transplant Congress
Unrecognized Synchronous Hepatocellcular Carcinoma Lesions in Explanted Liver Transplant Specimens
Introduction: Liver resection for early-stage hepatocellular carcinoma (HCC) is limited by high surgical risk in cirrhotics and high rates of intrahepatic recurrence. We postulated that…2015 American Transplant Congress
Suboptimal Vaccination Coverage After Liver Transplantation: Opportunity for Improvement
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Elimination of vaccine-preventable disease after solid organ transplantation (SOT) has the potential to improve outcomes. We evaluated immunization rates and the impact of directed recommendations…2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…2015 American Transplant Congress
Discrepancies Between the U.S. Transplant Registry and Cancer Registries Regarding Cancer Diagnoses in Transplant Recipients
1National Cancer Institute, Bethesda; 2Johns Hopkins Hospital, Baltimore; 3SRTR, Minneapolis.
Background: Transplant recipients have elevated cancer risk. US transplant centers report incident cancer diagnoses to the transplant network at yearly intervals, and these data are…2015 American Transplant Congress
Industry Payments to Transplant Surgeons
The Open Payments Program (OPP) was implemented to publicly disclose industry payments to physicians, enabling patients to be aware of potential conflicts of interest. Outcomes…2015 American Transplant Congress
Human CMV-Specific CD8 T Cells Exhibit Distinct Phenotypes and Distribution Patterns in Tissues and Circulation
IntroductionCMV persists and is controlled by T cells in multiple tissues; however, study of CMV responses has largely been limited to blood containing only 2-3%…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 170
- Next Page »